Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event
Together, the two acquisitions have an aggregate purchase price of approximately $700-$750 million which Viatris expects to fund with cash on hand.
- Together, the two acquisitions have an aggregate purchase price of approximately $700-$750 million which Viatris expects to fund with cash on hand.
- Ophthalmology is one of the key therapeutic areas of focus that the Company identified in February.
- Viatris Executive Chairman Robert J. Coury said: "Two years into our journey as Viatris, I am extremely pleased with the strength and execution of our business.
- We are pleased to announce this morning our agreements to acquire two high quality businesses to form a new ophthalmology franchise within Viatris.